OphthaliX updates website to reflect proposed acquisition of Israel-based Improved Vision Systems

Download PDF Copy

Jul 14 2015

NewsGuard 100/100 Score

OphthaliX Inc. (OTCQB: OPLI), a clinical-stage company focused on developing products that treat and improve sight for people living with ophthalmic disorders, and a subsidiary of Can-Fite BioPharma Ltd. (NYSE MKT: CANF), announced today it has launched an updated website, www.ophthaliX.com, to reflect its definitive agreement to acquire Israel-based Improved Vision Systems Ltd. (I.V.S.).

Upon completion of the acquisition of I.V.S., which is subject to the satisfaction of certain closing conditions, OphthaliX's portfolio of products in development will include two medical devices, Glance™, a desktop application, and vView™, wearable virtual reality goggles. These devices are based on breakthrough technologies that aim to diagnose, improve sight and offer therapy for a variety of ocular diseases and eye conditions including age related macular degeneration (AMD), glaucoma, diabetic retinopathy and oculo-motor pathologies.

OphthaliX continues to develop its drug candidate, CF101, a novel first in class small molecule orally bioavailable drug for ophthalmic indications, glaucoma and uveitis.

Source:

OpthaliX

Posted in: Business / Finance

Tags: Age-Related Macular Degeneration, Diabetic Retinopathy, Eye, Glaucoma, Macular Degeneration, Medical Devices, Molecule, Retinopathy, Uveitis, Virtual Reality

Comments (0)

Download PDF Copy

Suggested Reading

Screen time significantly associated with myopia in children, research shows

Screen time significantly associated with myopia in children, research shows

Childhood adversity linked to elevated health risks, differing by sex and stress

Childhood adversity linked to elevated health risks, differing by sex and stress

Does your ADHD medication increase your risk of glaucoma?

Does your ADHD medication increase your risk of glaucoma?

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.

Post a new comment

Post

Hi, I'm Azthena, you can trust me to find commercial scientific answers from News-Medical.net.

To start a conversation, please log into your AZoProfile account first, or create a new account.

Registered members can chat with Azthena, request quotations, download pdf's, brochures and subscribe to our related newsletter content.

A few things you need to know before we start. Please read and accept to continue.

Use of “Azthena” is subject to the terms and conditions of use as set out by OpenAI.
Content provided on any AZoNetwork sites are subject to the site Terms & Conditions and Privacy Policy.
Large Language Models can make mistakes. Consider checking important information.

I understand, and agree to receive occasional emails about Azthena such as usage tips and new feature announcements.

Please check the box above to proceed.

Great. Ask your question.

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...

New study identifies potential treatment for tauopathies using carbonic anhydrase inhibitors